Fecal microbiota transplantation (FMT) is an emerging therapeutic strategy with potential applications in the treatment of various diseases, particularly those associated with gut microbiome dysbiosis. However, clinical trials have demonstrated considerable variability in FMT efficacy—even among patients with the same disease. The heterogeneity of gut microbiota from donors is considered a key factor influencing patient outcomes. Consequently, the development of donor-recipient matching models h